Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | EOG | Common Stock | Options Exercise | $1.63M | +17.2K | +15.91% | $95.05 | 125K | Mar 3, 2022 | Direct | |
transaction | EOG | Common Stock | Disposed to Issuer | -$1.63M | -13.9K | -11.13% | $117.22 | 111K | Mar 3, 2022 | Direct | |
transaction | EOG | Common Stock | Tax liability | -$150K | -1.28K | -1.15% | $117.22 | 110K | Mar 3, 2022 | Direct | |
transaction | EOG | Common Stock | Options Exercise | $1.84M | +19.1K | +17.34% | $96.29 | 129K | Mar 3, 2022 | Direct | |
transaction | EOG | Common Stock | Disposed to Issuer | -$1.84M | -15.7K | -12.14% | $117.23 | 113K | Mar 3, 2022 | Direct | |
transaction | EOG | Common Stock | Tax liability | -$141K | -1.2K | -1.06% | $117.23 | 112K | Mar 3, 2022 | Direct | |
transaction | EOG | Common Stock | Options Exercise | $606K | +8.08K | +7.19% | $75.09 | 120K | Mar 3, 2022 | Direct | |
transaction | EOG | Common Stock | Disposed to Issuer | -$606K | -5.17K | -4.3% | $117.24 | 115K | Mar 3, 2022 | Direct | |
transaction | EOG | Common Stock | Tax liability | -$134K | -1.14K | -0.99% | $117.24 | 114K | Mar 3, 2022 | Direct | |
transaction | EOG | Common Stock | Options Exercise | $153K | +4.07K | +3.57% | $37.44 | 118K | Mar 3, 2022 | Direct | |
transaction | EOG | Common Stock | Disposed to Issuer | -$153K | -1.3K | -1.1% | $117.12 | 117K | Mar 3, 2022 | Direct | |
transaction | EOG | Common Stock | Tax liability | -$79.1K | -675 | -0.58% | $117.12 | 116K | Mar 3, 2022 | Direct | |
transaction | EOG | Common Stock | Sale | -$246K | -2.1K | -1.81% | $117.19 | 114K | Mar 3, 2022 | Direct | |
transaction | EOG | Common Stock | Sale | -$1.08M | -9.23K | -8.1% | $117.14 | 105K | Mar 3, 2022 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | EOG | Stock Appreciation Rights | Options Exercise | $0 | -17.2K | -100% | $0.00* | 0 | Mar 3, 2022 | Common Stock | 17.2K | $95.05 | Direct | F2 |
transaction | EOG | Stock Appreciation Rights | Options Exercise | $0 | -19.1K | -100% | $0.00* | 0 | Mar 3, 2022 | Common Stock | 19.1K | $96.29 | Direct | F3 |
transaction | EOG | Stock Appreciation Rights | Options Exercise | $0 | -8.08K | -66% | $0.00 | 4.16K | Mar 3, 2022 | Common Stock | 8.08K | $75.09 | Direct | F4 |
transaction | EOG | Stock Appreciation Rights | Options Exercise | $0 | -4.07K | -33.3% | $0.00 | 8.16K | Mar 3, 2022 | Common Stock | 4.07K | $37.44 | Direct | F5 |
Id | Content |
---|---|
F1 | The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $117.12 to $117.168, inclusive. The reporting person undertakes to provide to EOG Resources, Inc., any security holder of EOG Resources, Inc. or the staff of the United States Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
F2 | The SARs granted became exercisable in 25 percent increments beginning one year from the September 29, 2016 date of grant and on each of the next three grant date anniversaries. The SARs granted became fully exercisable on September 29, 2020. This exercise did not involve any open-market sale of the Issuer's Common Stock. |
F3 | The SARs granted became exercisable in increments of 33%, 33% and 34% on each of the first three anniversaries, respectively, of the September 25, 2017 date of grant. The SARs granted became fully exercisable on September 25, 2020. This exercise did not involve any open-market sale of the Issuer's Common Stock. |
F4 | The SARs granted become exercisable in increments of 33%, 33% and 34% on each of the first three anniversaries, respectively, of the September 26, 2019 date of grant. The SARs granted will become fully exercisable on September 26, 2022. This exercise did not involve any open-market sale of the Issuer's Common Stock. |
F5 | The SARs granted become exercisable in increments of 33.3%, 33.3% and 33.4% on each of the first three anniversaries, respectively, of the September 28, 2020 date of grant. The SARs granted will become fully exercisable on September 28, 2023. |